Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for the management of patients with immune-mediated inflammatory disease (IMID) receiving immunosuppressive (IS) therapeutics.
To determine if IS therapeutic type affects COVID-19 risk among patients with IMID.
We conducted a retrospective cohort analysis of Henry Ford Health System patients tested for COVID-19 between February 1 and April 18, 2020, treated with IS medication for IMID. Therapeutic class of IS medication, comorbidities, and demographic factors were combined into multivariate models to determine predictors of COVID-19 infection, admission, ventilation, and mortality.
Of 213 patients with IMID, 36.2% tested positive for COVID-19, and they had no greater odds of being hospitalized or requiring ventilation relative to the general population. No IS therapeutic worsened the course of disease after multivariate correction, although multidrug regimens and biologics predicted an increased and decreased rate of hospitalization, respectively, with the latter driven by tumor necrosis factor α inhibitors.
A single-center study somewhat limits the generalization to community-based settings. Only patients tested for COVID-19 were analyzed.
IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and tumor necrosis factor α inhibitors may decrease the odds of severe infection.Le texte complet de cet article est disponible en PDF.
Key words : autoimmune disease, biologics, coronavirus, COVID-19, DMARDs, immune-mediated inflammatory diseases, immunosuppression, SARS-CoV-2
Abbreviations used : CI, DMARD, HFHS, IL, IMID, IS, OR, PCR, SARS-CoV-2, TNF
| Funding sources: None.
| Conflicts of interest: None disclosed.
| IRB approval status: Reviewed and approved by Henry Ford Health System IRB (no. 13768).
| Reprints not available from the authors.